Eli Lilly’s profit doubled in the fourth quarter driven by its successful diabetes and obesity treatments, Mounjaro and Zepbound. The company reported a 60% surge in Mounjaro sales to $3.53 billion, while Zepbound brought in $1.9 billion.
The top-selling products are part of a growing trend of GLP-1 receptor agonists that have gained popularity due to their weight loss benefits. Eli Lilly’s forecast for 2025 is mostly positive, with adjusted earnings ranging from $22.50 to $24 per share and revenue expected to fall between $58 billion and $61 billion.
The company’s strong performance has been driven by the success of these treatments, which compete with similar medications from Novo Nordisk. Analysts expect significant sales growth for Mounjaro and Zepbound in 2025, with some forecasting over $18 billion and $10 billion respectively.
Despite the positive earnings report, Eli Lilly’s stock slipped 1% to $831.64 in premarket trading.
Source: https://abcnews.go.com/Business/wireStory/diabetes-obesity-drugs-fuel-eli-lilly-profit-final-118526193